Fresenius SE KGaAXSWX:FRE 71 EBIT per Share is CHF4.20 as of Mar. 2026. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF32.85 (Fairly Valued). The stock has 5 warning signs investors should review. Among 532 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 58.46% on this metric.
Fresenius SE KGaA's EBIT per Share for the
three
months ended in Mar. 2026 was CHF0.97.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF4.20.
During the past 12 months, the average EBIT per Share Growth Rate of Fresenius SE KGaA was -3.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 6.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -15.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Fresenius SE KGaA's EBIT per Share or its related term are showing as below:
XSWX:FRE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -50 Med: 3.8 Max: 55.5
Current: 6.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Fresenius SE KGaA was 55.50% per year. The lowest was -50.00% per year. And the median was 3.80% per year.
XSWX:FRE's 3-Year EBIT Growth Rate is ranked worse than 58.46% of 532
companies
in the Healthcare Providers & Services industry
Industry Median: 11.75
vs XSWX:FRE: 6.30
Fresenius SE KGaA (XSWX:FRE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Fresenius SE KGaA EBIT per Share Related Terms
Fresenius SE KGaA EBIT per Share Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF4.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a EBIT per Share of CHF4.20 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fresenius SE KGaA and its competitors. According to the industry distribution chart, Fresenius SE KGaA ranks #311 out of 532 companies in the Healthcare Providers & Services industry, placing it in the top 58.5%.
Is Fresenius SE KGaA's EBIT per Share too high?
Fresenius SE KGaA's current EBIT per Share is CHF4.20. Based on the distribution chart, Fresenius SE KGaA ranks #311 out of 532 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #311 out of 532 companies for EBIT per Share. This places Fresenius SE KGaA in the lower half of its industry. The industry median EBIT per Share is 11.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.75, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current EBIT per Share is CHF4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF32.85, compared to a current price of CHF35.86 — trading 9.2% above its estimated fair value. The current EBIT per Share is CHF4.20. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current EBIT per Share is CHF4.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF35.86 is trading 9.2% above its estimated GF Value™ of CHF32.85.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
EBIT per Share: CHF4.20
GF Value™: CHF32.85 vs. price of CHF35.86 (9.2% above fair value)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
